Radiopharm Theranostics (RDPTF) Current Deferred Revenue (2024 - 2026)

Radiopharm Theranostics (RDPTF) has reported Current Deferred Revenue for 3 consecutive years, with $5720.3 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Current Deferred Revenue fell 48.09% year-over-year to $5720.3 in Q2 2026; TTM through Jun 2026 was $5720.3, a 48.09% decrease from a year earlier, with the FY2026 full-year figure at $5476.8, down 99.68% from the prior year.
• Current Deferred Revenue was $5720.3 for Q2 2026 at Radiopharm Theranostics, down from $11019.0 in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $3.2 million in Q4 2024 and troughed at $5720.3 in Q2 2026.
• A 3-year average of $1.1 million and a median of $11019.0 in 2025 frame the typical range for Current Deferred Revenue.
• The widest YoY moves for Current Deferred Revenue: up 48.09% in 2026, down 48.09% in 2026.
• Over 3 years, Current Deferred Revenue stood at $3.2 million in 2024, then tumbled by 99.65% to $11019.0 in 2025, then plunged by 48.09% to $5720.3 in 2026.
• The last three Current Deferred Revenue figures came in at $5720.3 (Q2 2026), $11019.0 (Q2 2025), and $3.2 million (Q4 2024), per Business Quant data.